Some well-known life-science investors do not publish a pharmaceutical process, crystallization or manufacturing-equipment thesis, yet they do publish active venture or strategic investing in therapeutics, platforms, tools or adjacent industrial biotechnology. This page lists a selection of those firms for discoverability only. It is not a claim that they are seeking process startups, that they have open applications, or that they are “entirely capable” of funding any given technology.
The Grant Lattice is independent. This broader list is informational and compiled from public sources. It is NOT a verified list of investors in pharmaceutical process, crystallization or manufacturing equipment. Inclusion means only that the firm publishes life-science (or clearly life-science-adjacent) venture or strategic investment activity — not that they are seeking process startups, have open applications, or are “entirely capable” of funding your specific technology. Always confirm current focus on the firm’s official website.
14 firms · entries checked 05 Nov 2026 · see also direct-fit investment groups · consortia & centres.
Process fit unconfirmedCorporate venture arm · Global (Pfizer strategic corporate venture)
- Type
- Corporate venture arm (Pfizer Inc.)
- Typical stage (as published)
- Seed through IPO (officially emphasises early-stage new investments); typical initial investment stated as $5–20 million
- Documented investment scope
- Official page — Pfizer’s strategic corporate venture capital arm investing globally in innovative biopharmaceutical companies; core focus Oncology, Inflammation & Immunology, Cardiovascular, Metabolic/Obesity, Vaccines; also platform technology companies with pipelines aligned to those areas.
- Why it appears on this broader list
- Active, named corporate venture programme with a published life-science investment strategy. Useful to know exists when exploring equity after non-dilutive routes — not because a manufacturing mandate is published.
- What remains unverified
- No current official Pfizer Ventures mandate for pharmaceutical process equipment, crystallization hardware or continuous manufacturing was found on the pages checked. Older manufacturing/facility examples (if any) are historical context only and do not prove current appetite or open applications.
- Published approach route
- Team names/titles published (no emails or open portal observed). The official Venture Investments page lists named Pfizer Ventures team members and titles. No email addresses, open application portal, or public intake form appeared in the page content retrieved.
Reading notes
- Name the investment arm (Pfizer Ventures), not “Pfizer” alone.
- Do not infer manufacturing interest from Pfizer Inc.’s size or from historical facility deals.
Sources checked (3)
Official site · Checked 05 Nov 2026
About this listing
The Grant Lattice is independent. This broader list is informational and compiled from public sources. It is NOT a verified list of investors in pharmaceutical process, crystallization or manufacturing equipment. Inclusion means only that the firm publishes life-science (or clearly life-science-adjacent) venture or strategic investment activity — not that they are seeking process startups, have open applications, or are “entirely capable” of funding your specific technology. Always confirm current focus on the firm’s official website.
Process fit unconfirmedCorporate venture fund · Global (team Basel, Switzerland and South San Francisco, USA)
- Type
- Corporate venture fund (Roche)
- Typical stage (as published)
- Focus on Series A (will invest later); therapeutics often preclinical; diagnostics preferably about 12–18 months to launch
- Documented investment scope
- Official investing page — private companies with innovative medicines, diagnostics and technologies; CHF 3–10 million typical first-round range with ~15% ownership stake (varies); evergreen fund with follow-on reserves.
- Why it appears on this broader list
- Named Roche corporate venture fund with a published life-science mandate spanning medicines and diagnostics/technologies.
- What remains unverified
- No published current remit for pharma process equipment, crystallization or continuous manufacturing. Series A / preclinical therapeutics focus is not a process-hardware pipeline.
- Published approach route
- Not published as an open portal. Fund overview and investing pages are public. No open application portal was found on the pages checked; contact routes are not published as an intake form there.
Reading notes
- Corporate venture of Roche; independent decision mandate stated on the investing page.
- Diagnostics timeline language is about product launch readiness, not manufacturing-equipment investing.
Sources checked (3)
- Roche Venture Fund overview — “Invest in life science companies in pharmaceuticals, diagnostics and digital health” (checked 05 Nov 2026)
- Roche Venture Fund — Investing — “We invest in private companies with innovative medicines, diagnostics and technologies.” (checked 05 Nov 2026)
- Roche Venture Fund — typical investment — “We focus on Series A investments though we will invest later. For therapeutics, we like to invest in preclinical companies. For diagnostics, we prefer 12-18 months to launch.” (checked 05 Nov 2026)
Official site · Checked 05 Nov 2026
About this listing
The Grant Lattice is independent. This broader list is informational and compiled from public sources. It is NOT a verified list of investors in pharmaceutical process, crystallization or manufacturing equipment. Inclusion means only that the firm publishes life-science (or clearly life-science-adjacent) venture or strategic investment activity — not that they are seeking process startups, have open applications, or are “entirely capable” of funding your specific technology. Always confirm current focus on the firm’s official website.
Process fit unconfirmedLife-science venture investor · Copenhagen, London, Singapore, Boston, San Francisco (as published)
- Type
- Life-science venture investor (Novo Holdings A/S — Venture Investments team)
- Typical stage (as published)
- Early-stage translatable science through commercial-stage products (private and public)
- Documented investment scope
- Official Venture Investments page — one of the largest life-science venture investors; primarily companies developing innovative drugs and novel technologies in biotech and medtech; typically leads or co-leads private deals with board participation.
- Why it appears on this broader list
- Large, active, evergreen life-science venture programme with a clear published biotech/medtech remit. Distinct from Novo Holdings Principal Investments (buyouts of established companies).
- What remains unverified
- No published current mandate for crystallization hardware or pharma continuous-manufacturing equipment. Do not treat Principal Investments buyouts (e.g. large CDMO deals) as proof of Venture appetite for process startups.
- Published approach route
- Published corporate contact (no open portal found). Team/contact emails appear via Novo Holdings corporate pages (Info@novoholdings.dk listed). No open startup application portal was found on the Venture Investments page checked.
Reading notes
- Keep Venture Investments and Principal Investments separate. This card is Venture only.
- Principal Investments is documented for awareness but not listed as a spin-out VC target.
Sources checked (3)
Official site · Checked 05 Nov 2026
About this listing
The Grant Lattice is independent. This broader list is informational and compiled from public sources. It is NOT a verified list of investors in pharmaceutical process, crystallization or manufacturing equipment. Inclusion means only that the firm publishes life-science (or clearly life-science-adjacent) venture or strategic investment activity — not that they are seeking process startups, have open applications, or are “entirely capable” of funding your specific technology. Always confirm current focus on the firm’s official website.
Process fit unconfirmedIndependent biotechnology venture capital firm · Transatlantic — West Coast USA and London, UK (offices also described historically in Redwood City / Philadelphia / London)
- Type
- Independent biotechnology venture capital firm (spun out from GSK; not a current GSK corporate venture arm)
- Typical stage (as published)
- Biotechnology company building / venture (back-and-build); specific check sizes not published on the home page checked
- Documented investment scope
- Official site — biotechnology VC partnering with founders to translate innovative science into medicines; back-and-build approach; transatlantic investing team.
- Why it appears on this broader list
- Active independent biotech VC with a published medicines-building remit. Listed so researchers do not confuse it with a current GSK corporate venture programme.
- What remains unverified
- No published process/crystallization/manufacturing-equipment mandate. Not GSK’s current CVC.
- Published approach route
- Not published as an open portal. Office addresses published on the home page. Media email listed for press; no open application portal found on the pages checked.
Reading notes
- Independent since the GSK spin-out; do not label as GSK Ventures.
Sources checked (3)
- SR One home — “A biotechnology venture capital firm, partnering with founders and entrepreneurs to translate innovative science into medicines.” (checked 05 Nov 2026)
- SR One — back-and-build — “SR One takes a back-and-build approach to its investments.” (checked 05 Nov 2026)
- SR One — geography — “SR One’s investing team is situated in key biotechnology hubs on the West Coast, USA and London, UK.” (checked 05 Nov 2026)
Official site · Checked 05 Nov 2026
About this listing
The Grant Lattice is independent. This broader list is informational and compiled from public sources. It is NOT a verified list of investors in pharmaceutical process, crystallization or manufacturing equipment. Inclusion means only that the firm publishes life-science (or clearly life-science-adjacent) venture or strategic investment activity — not that they are seeking process startups, have open applications, or are “entirely capable” of funding your specific technology. Always confirm current focus on the firm’s official website.
Process fit unconfirmedGlobal healthcare investment firm · Global (North America, Asia, Europe per private-equity description); founded in New York City
- Type
- Global healthcare investment firm (private equity / venture, public equity, private credit/royalty)
- Typical stage (as published)
- Seed-stage venture through growth equity and public companies (strategy-dependent)
- Documented investment scope
- Official About page — invests in companies in discovery and development of biopharmaceutical products, medical technologies, devices, diagnostics, drug discovery tools, and healthcare IT/services; private equity from start-ups through growth equity.
- Why it appears on this broader list
- Large dedicated healthcare investor with an explicit multi-strategy life-science remit including tools — still without a verified process-manufacturing mandate.
- What remains unverified
- No official current crystallization / continuous-manufacturing / pharma-process equipment thesis found. Breadth of healthcare investing ≠ fit for a specific process spin-out.
- Published approach route
- Not published as an open portal. Firm site is public. No open application portal was found on the About page checked.
Reading notes
- Multi-strategy firm; confirm which strategy (if any) fits a process tools company before outreach.
Sources checked (3)
- OrbiMed About — “invests in companies engaged in the discovery and development of biopharmaceutical products, medical technologies, medical devices, diagnostics, drug discovery tools, and healthcare information technology and services companies.” (checked 05 Nov 2026)
- OrbiMed — Private Equity strategy — “OrbiMed's private equity strategy is broad and flexible, investing from start-ups through growth equity.” (checked 05 Nov 2026)
- OrbiMed — geography — “We invest globally, including across North America, Asia, and Europe.” (checked 05 Nov 2026)
Official site · Checked 05 Nov 2026
About this listing
The Grant Lattice is independent. This broader list is informational and compiled from public sources. It is NOT a verified list of investors in pharmaceutical process, crystallization or manufacturing equipment. Inclusion means only that the firm publishes life-science (or clearly life-science-adjacent) venture or strategic investment activity — not that they are seeking process startups, have open applications, or are “entirely capable” of funding your specific technology. Always confirm current focus on the firm’s official website.
Process fit unconfirmedIndependent venture / company-creation firm · Firm tagline on About page includes Everywhere; no office list was in the About page content retrieved
- Type
- Independent venture / company-creation firm (disruptive science; About page does not itself label a single therapeutic sector)
- Typical stage (as published)
- Company formation and building with flexible cheque sizing (About page: as little as $50K to hundreds of millions per company)
- Documented investment scope
- Official About page — backs disruptive science companies; follows the science to found companies based on revolutionary technologies; flexible investment sizing from small cheques to large follow-ons; build disruptive companies. Everywhere.
- Why it appears on this broader list
- Published company-creation / science-founding investor. Listed for discoverability of that model — not as a confirmed process-equipment investor. (Sector branding beyond the About page text is not treated as proof here.)
- What remains unverified
- About page content retrieved does not state a pharmaceutical crystallization, continuous-manufacturing, or even an explicit life-sciences-only mandate. No process-equipment thesis found there.
- Published approach route
- Not published as an open portal. Firm site is public. No open application portal found on the About page checked.
Reading notes
- Company-creation model; many opportunities are originated inside the firm’s network rather than via open cold applications.
- Do not upgrade life-sciences VC from the About page alone; that page retrieved text is science/technology company founding, not a sector label.
Sources checked (3)
- ARCH Venture Partners — About — “We follow the science to found companies based on revolutionary technologies that can impact people’s lives.” (checked 05 Nov 2026)
- ARCH — investment flexibility — “ARCH has backed disruptive science companies with as little as $50K to as much as hundreds of millions of dollars, per company.” (checked 05 Nov 2026)
- ARCH — company building — “We back great science. We partner with amazing people. We build disruptive companies. Everywhere.” (checked 05 Nov 2026)
Official site · Checked 05 Nov 2026
About this listing
The Grant Lattice is independent. This broader list is informational and compiled from public sources. It is NOT a verified list of investors in pharmaceutical process, crystallization or manufacturing equipment. Inclusion means only that the firm publishes life-science (or clearly life-science-adjacent) venture or strategic investment activity — not that they are seeking process startups, have open applications, or are “entirely capable” of funding your specific technology. Always confirm current focus on the firm’s official website.
Process fit unconfirmedMulti-stage healthcare / life-sciences / planetary-health investor · Boston, San Francisco, New York, Shanghai (published hubs)
- Type
- Multi-stage healthcare / life-sciences / planetary-health investor
- Typical stage (as published)
- NewCo / seed through venture, crossover, IPO and public markets; structured capital also offered
- Documented investment scope
- Official About page — funds and builds companies from evidence to enterprise; multi-stage capital across healthcare and life sciences; hub email request@racap.com published.
- Why it appears on this broader list
- Full-lifecycle life-science investor with published company-creation and venture activity.
- What remains unverified
- No published current thesis for crystallization hardware or pharma process equipment on the About page checked.
- Published approach route
- Published contact email. Published hub email request@racap.com on the About page. No open intake portal found there.
Reading notes
- Planetary-health practice is separate from therapeutics; do not conflate.
Sources checked (3)
- RA Capital — About — “RA Capital funds and builds companies from evidence to enterprise. We help transform breakthrough science into transformative therapeutics” (checked 05 Nov 2026)
- RA Capital — multi-stage — “RA Capital is a multi-stage investor across healthcare, life sciences, and planetary health” (checked 05 Nov 2026)
- RA Capital — hub contact — “Email our hub team at request@racap.com.” (checked 05 Nov 2026)
Official site · Checked 05 Nov 2026
About this listing
The Grant Lattice is independent. This broader list is informational and compiled from public sources. It is NOT a verified list of investors in pharmaceutical process, crystallization or manufacturing equipment. Inclusion means only that the firm publishes life-science (or clearly life-science-adjacent) venture or strategic investment activity — not that they are seeking process startups, have open applications, or are “entirely capable” of funding your specific technology. Always confirm current focus on the firm’s official website.
Process fit unconfirmedCompany-creation / bioplatform pioneering firm · Not stated as a country list on the About page content retrieved
- Type
- Company-creation / bioplatform pioneering firm (not a generic open VC application desk)
- Typical stage (as published)
- In-house company conception, creation and capitalization; multiple new companies per year as published
- Documented investment scope
- Official About page — invents and builds companies; companies founded 120+; new companies each year 6–8 (as published on that page); focus on bioplatforms and patentable white spaces; ideas conceived, created and capitalized in-house.
- Why it appears on this broader list
- Major company-creation platform in life sciences. Worth knowing as a model — usually originates companies internally rather than funding arbitrary outside process startups.
- What remains unverified
- Not a published open manufacturing-equipment investor. In-house origination ≠ open applications for external process hardware teams.
- Published approach route
- Not published as an open portal (company creation is largely in-house). Careers and about pages are public. No open external application portal for investment was found on the About page checked.
Reading notes
- Treat as company creation, not a drop-box for unsolicited process decks.
Sources checked (3)
Official site · Checked 05 Nov 2026
About this listing
The Grant Lattice is independent. This broader list is informational and compiled from public sources. It is NOT a verified list of investors in pharmaceutical process, crystallization or manufacturing equipment. Inclusion means only that the firm publishes life-science (or clearly life-science-adjacent) venture or strategic investment activity — not that they are seeking process startups, have open applications, or are “entirely capable” of funding your specific technology. Always confirm current focus on the firm’s official website.
Process fit unconfirmedBiotechnology venture firm with a company-creation model · Boston and San Francisco offices published
- Type
- Biotechnology venture firm with a company-creation model
- Typical stage (as published)
- Extended seed / discovery validation before launch; then launch and build
- Documented investment scope
- Official Approach page — harnesses novel science and technology to build companies that create medicines; distinctive company-creation model; 70+ companies launched; extended seed-stage validation before launch.
- Why it appears on this broader list
- Leading company-creation biotech VC. Listed for discoverability of the model, not as a confirmed process-equipment fit.
- What remains unverified
- No published crystallization / continuous-manufacturing equipment mandate on the Approach page checked.
- Published approach route
- Published office contacts (no open portal found). Office addresses and phone numbers published on the Approach page. No open application portal found there.
Reading notes
- Company creation with long seed validation; cold process-equipment pitches are unlikely to match the model.
Sources checked (3)
- Third Rock — Approach — “we harness novel science and technology to build companies that create medicines that can transform the lives of patients” (checked 05 Nov 2026)
- Third Rock — company creation — “a leading biotechnology venture capital firm with a distinctive company creation model” (checked 05 Nov 2026)
- Third Rock — seed validation — “the extended time we take at the seed stage, validating mechanisms and maturing a lead program well before a company launches” (checked 05 Nov 2026)
Official site · Checked 05 Nov 2026
About this listing
The Grant Lattice is independent. This broader list is informational and compiled from public sources. It is NOT a verified list of investors in pharmaceutical process, crystallization or manufacturing equipment. Inclusion means only that the firm publishes life-science (or clearly life-science-adjacent) venture or strategic investment activity — not that they are seeking process startups, have open applications, or are “entirely capable” of funding your specific technology. Always confirm current focus on the firm’s official website.
Process fit unconfirmedBiotechnology company-building venture firm · Life-science entrepreneurship focus (firm-published US biotech franchise)
- Type
- Biotechnology company-building venture firm
- Typical stage (as published)
- Creating and building biotech startups (incubator / company creation as published)
- Documented investment scope
- Official home page — creating and building breakthrough biotechs for over 30 years; partnering with life-science entrepreneurs; translating groundbreaking science into medicines; publishes startup-launch counts.
- Why it appears on this broader list
- Established biotech company builder with a clear medicines remit.
- What remains unverified
- No published pharma-process manufacturing or crystallization-equipment thesis on the home page checked.
- Published approach route
- Not published as an open portal. Firm site is public. No open application portal found on the home page checked.
Reading notes
- Company-building franchise; medicines focus dominates public messaging.
Sources checked (3)
- Atlas Venture home — “Creating and building breakthrough biotechs for over 30 years” (checked 05 Nov 2026)
- Atlas — people — “Partnering with the world's best life science entrepreneurs” (checked 05 Nov 2026)
- Atlas — impact — “Translating groundbreaking science into life-changing medicines” (checked 05 Nov 2026)
Official site · Checked 05 Nov 2026
About this listing
The Grant Lattice is independent. This broader list is informational and compiled from public sources. It is NOT a verified list of investors in pharmaceutical process, crystallization or manufacturing equipment. Inclusion means only that the firm publishes life-science (or clearly life-science-adjacent) venture or strategic investment activity — not that they are seeking process startups, have open applications, or are “entirely capable” of funding your specific technology. Always confirm current focus on the firm’s official website.
Process fit unconfirmedBiotechnology venture firm with in-house discovery engines · Multiple locations; discovery engines and academic partnerships as published
- Type
- Biotechnology venture firm with in-house discovery engines
- Typical stage (as published)
- Company launch from discovery engines and academic partnerships
- Documented investment scope
- Official home page — discovery engines of multi-disciplinary scientists enabling launch of novel biotechnology companies with academic founders; decades of VC/pharma/biotech experience claimed in firm stats.
- Why it appears on this broader list
- Discovery-engine company creation aimed at academic founders — a real life-science equity path, still without verified process-hardware fit.
- What remains unverified
- No published crystallization / continuous-manufacturing equipment mandate on the home page checked.
- Published approach route
- Not published as an open portal. Firm site is public. No open application portal found on the home page checked.
Reading notes
- Discovery-engine model is selective; not an open manufacturing call.
Sources checked (3)
Official site · Checked 05 Nov 2026
About this listing
The Grant Lattice is independent. This broader list is informational and compiled from public sources. It is NOT a verified list of investors in pharmaceutical process, crystallization or manufacturing equipment. Inclusion means only that the firm publishes life-science (or clearly life-science-adjacent) venture or strategic investment activity — not that they are seeking process startups, have open applications, or are “entirely capable” of funding your specific technology. Always confirm current focus on the firm’s official website.
Process fit unconfirmedLife-science venture firm · Life-science investing (firm describes building companies around the world)
- Type
- Life-science venture firm (venture + Opportunities strategies)
- Typical stage (as published)
- Early-stage / company building (including 4:59 incubation toward Series A); Opportunities covers later-stage private and small/mid-cap public
- Documented investment scope
- Official Strategy page — portfolio diversified across biopharmaceutical, drug delivery technology and research instrument sectors; evaluates platform technologies, corporate spin-offs and shorter-cycle products; 4:59 effort discovers, incubates and funds breakthrough science toward Series A.
- Why it appears on this broader list
- One of the few large life-science VCs that explicitly names research instruments alongside biopharma and drug delivery — still not a verified crystallization/process mandate.
- What remains unverified
- Research-instrument language is sector breadth, not a published pharmaceutical continuous-manufacturing or crystallization-equipment thesis. Do not upgrade to direct-fit without new official process proof.
- Published approach route
- Not published as an open portal. Strategy and portfolio pages are public. No open application portal found on the Strategy page checked.
Reading notes
- Instrument/drug-delivery wording is why this card is useful on the broader list — still unverified for process fit.
Sources checked (3)
- 5AM Ventures — Strategy — “5AM’s portfolio of advanced life science technologies is diversified within the healthcare industry’s biopharmaceutical, drug delivery technology and research instrument sectors.” (checked 05 Nov 2026)
- 5AM — 4:59 incubation — “4:59 is our hands-on internal effort to discover, incubate, and fund breakthrough science… to establish proof-of-concept data that will enable a Series A Financing.” (checked 05 Nov 2026)
- 5AM Opportunities — “5AM Opportunities Strategy invests in small and mid-cap public and later-stage private biotech and life science companies.” (checked 05 Nov 2026)
Official site · Checked 05 Nov 2026
About this listing
The Grant Lattice is independent. This broader list is informational and compiled from public sources. It is NOT a verified list of investors in pharmaceutical process, crystallization or manufacturing equipment. Inclusion means only that the firm publishes life-science (or clearly life-science-adjacent) venture or strategic investment activity — not that they are seeking process startups, have open applications, or are “entirely capable” of funding your specific technology. Always confirm current focus on the firm’s official website.
Process fit unconfirmedCorporate venture capital · Ludwigshafen (GER), Boston (USA), Shanghai (CHN) among published locations; evergreen fund
- Type
- Corporate venture capital (BASF Group)
- Typical stage (as published)
- Typically after technological and market proof of concept (Seed to Series B described in BASF features)
- Documented investment scope
- Official BVC page — corporate VC of BASF investing in young companies and funds related to current and future BASF businesses; fields include biotechnology and new materials among others.
- Why it appears on this broader list
- Industrial/chemicals corporate VC with an explicit biotechnology investment field — process-adjacent chemistry, not a confirmed pharma crystallization investor.
- What remains unverified
- No clear official mandate for pharmaceutical process equipment or crystallization hardware. Industrial biotech ≠ pharma process spin-out fit.
- Published approach route
- Published communications contact. Communications contact email published on the BVC page. No open startup intake portal found there.
Reading notes
- Chemicals/materials CVC; keep industrial biotech separate from pharma process claims.
Sources checked (3)
- BASF Venture Capital — “We are the corporate venture capital company of the BASF Group. Since 2001, we have been investing worldwide in young, fast-growing companies and funds related to current and future businesses of BASF.” (checked 05 Nov 2026)
- BASF VC — investment fields — “We invest and collaborate in fields that shape the future: CO 2 reduction, the circular economy, new materials, biotechnology, as well as artificial intelligence and software solutions.” (checked 05 Nov 2026)
- BASF VC — stage — “We typically invest after technological and market proof of concept has been established.” (checked 05 Nov 2026)
Official site · Checked 05 Nov 2026
About this listing
The Grant Lattice is independent. This broader list is informational and compiled from public sources. It is NOT a verified list of investors in pharmaceutical process, crystallization or manufacturing equipment. Inclusion means only that the firm publishes life-science (or clearly life-science-adjacent) venture or strategic investment activity — not that they are seeking process startups, have open applications, or are “entirely capable” of funding your specific technology. Always confirm current focus on the firm’s official website.
Process fit unconfirmedCorporate venture capital · Offices in Germany, USA and China
- Type
- Corporate venture capital (Evonik)
- Typical stage (as published)
- Early stage to growth stage; up to about €15 million per portfolio company (as published)
- Documented investment scope
- Official pages — strategic CVC with ~55 investments since 2012; Precision Biosolutions areas include nucleic-acid medicines & drug delivery, cell-culture solutions, biosurfactants, cosmetic actives; separate energy and circular-economy growth areas.
- Why it appears on this broader list
- Specialty-chemicals CVC with an explicit Precision Biosolutions growth area that names drug delivery and cell-culture solutions — life-science-adjacent without a verified crystallization mandate.
- What remains unverified
- No published current remit for pharmaceutical crystallization or continuous-manufacturing equipment. Energy/circular themes are not pharma process fit.
- Published approach route
- Not published as an open portal. Who-we-are page invites partnering language; no open application form URL was found on the pages checked.
Reading notes
- Cite Precision Biosolutions carefully; do not invent a crystallization thesis.
Sources checked (3)
Official site · Checked 05 Nov 2026
About this listing
The Grant Lattice is independent. This broader list is informational and compiled from public sources. It is NOT a verified list of investors in pharmaceutical process, crystallization or manufacturing equipment. Inclusion means only that the firm publishes life-science (or clearly life-science-adjacent) venture or strategic investment activity — not that they are seeking process startups, have open applications, or are “entirely capable” of funding your specific technology. Always confirm current focus on the firm’s official website.